Nosocomial outbreak-derived Serratia marcescens: In vitro susceptibility to antimicrobial agents in comparison with carbapenem-resistant strains

Acta Medica et Biologica

Volumn 50, Issue 4, 2002, Pages 177-183

  Taneike, Ikue ^a   Nakagawa, Saori ^a   Iwaya, Akira ^a   Yamamoto, Tatsuo ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

A nosocomial outbreak; In vitro susceptibility; Serratia marcescens

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFACLOR; CEFAZOLIN; CEFIXIME; CEFOPERAZONE; CEFOTAXIME; CEFOTIAM; CEFTAZIDIME; CEFTRIAXONE; CEPHEM DERIVATIVE; FOSFOMYCIN; GLUCOSE 6 PHOSPHATE; LATAMOXEF; MACROLIDE; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; SULPERAZON; SULTAMICILLIN; TRIMETHOPRIM; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; FEVER; HOSPITAL INFECTION; JAPAN; MINIMUM INHIBITORY CONCENTRATION; SEPSIS; SERRATIA MARCESCENS;

BACTERIA (MICROORGANISMS); SERRATIA MARCESCENS;

EID: 0037003921     PISSN: 05677734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hejazi A, Aucken HM, Falkiner FR: Epidemiology and susceptibility of Serratia marcescens in a large general hospital over an 8-year period. J Hosp Infect 45: 42-46, 2000.
2. Hejazi A, Falkiner FR: Serratia marcescens. J Med Microbiol 46: 903-912, 1997.
3. IMP) in gram-negative rods resistant to broad-spectrum β-lactams. J Clin Microbiol 34: 2909-2913, 1996.
4. Queenan AM, Torres-Viera C, Gold HS, Carmeli Y, Eliopoulos GM, Moellering RC Jr, Quinn JP, Hindler J, Medeiros AA, Bush K: SME-type carbapenemhydrolyzing class A β-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother 44: 3035-3039, 2000.
5. Gales AC, Biedenbach DJ, Winokur P, Hacek DM, Pfaller MA, Jones RN: Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: results from the MYSTIC programme. Diagn Microbiol Infect Dis 39: 125-127, 2001.
6. Yano H, Kuga A, Okamoto R, Kitasato H, Kobayashi T, Inoue M: Plasmid-encoded metallo-β-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Antimicrob Agents Chemother 45: 1343-1348, 2001.
7. Yum JH, Yong D, Lee K, Kim HS, Chong Y: A new integron carrying VIM-2 metallo-β-lactamase gene cassette in a Serratia marcescens isolate. Diagn Microbiol Infect Dis 42: 217-219, 2002.
8. Report of the study group for disease of unknown cause. Tokyo: Bureau of Public Health Tokyo Metropolitan Government 2000. (in Japanese)
9. The report of nosocomial Serratia marcescens outbreak in Sakai city. Sakai city government public health and welfare bureau 2000. (in Japanese)
10. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing, 12th informational supplement. National Committee for Clinical Laboratory Standards, Wayne, Pa: PM100-S12, 2002.
11. Japan Society of Chemotherapy: Committee report. Chemotherapy (Tokyo) 29: 76-79, 1981.
12. Japan Society of Chemotherapy: Committee report: methods of sensitivity testing for sulfamethoxazoletrimethoprim combination product. Chemotherapy (Tokyo) 21: 67-76, 1973.
13. Dette GA, Knothe H, Schonenbach B, Plage G: Comparative study of fosfomycin activity in Mueller-Hinton media and in tissues. J Antimicrob Chemother 11: 517-524, 1983.
14. Bush K, Jacoby GA, Medeiros AA: A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39: 1211-1233, 1995.
15. Philippon A, Arlet G, Jacoby GA: Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 46: 1-11, 2002.
16. Koh B, Izawa Y, Sugiyama H, Aoyama H, Komiya I: Transfer of fosfomycin into human burn blister fluid and its pharmacokinetic analysis. Jpn J Antibiot 39: 2863-2868, 1986. (in Japanese)
17. Fluit AC, Schmitz FJ: Class 1 integrons, gene cassettes, mobility, and epidemiology. Eur J Clin Microbiol Infect Dis 18: 761-770, 1999.
18. White PA, McIver CJ, Rawlinson WD: Integrons and gene cassettes in the Enterobacteriaceae. Antimicrob Agents Chemother 45: 2658-2661, 2001.
19. Nordmann P, Poirel L: Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 8: 321-331, 2002.
20. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864-874, 1992.
21. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G: Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390: 518-521, 1997.
22. Varga K, Wagner JA, Bridgen DT, Kunos G: Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12: 1035-1044, 1998.
23. Wang Y, Liu Y, Sarker KP, Nakashima M, Serizawa T, Kishida A, Akashi M, Nakata M, Kitajima I, Maruyama I: Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FEBS Lett 470: 151-155, 2000.